文献速递妇科

不同种族和民族患者高肿瘤突变负荷、高微卫星不稳定及错配修复缺陷的分子特征:来自多机构子宫内膜癌分子靶向治疗联盟(ECMT2)的真实世界数据

Molecular characteristics by race and ethnicity of patients with high tumor mutational burden, high microsatellite instability, and mismatch repair deficiency: Real-world data from the multi-institutional Endometrial cancer Molecularly Targeted Therapy Consortium (ECMT2).
PubMed 文献 · Gynecol Oncol · 2025-07-11

本研究基于多机构子宫内膜癌分子靶向治疗联盟的真实世界数据,纳入742例子宫内膜癌患者,分析高肿瘤突变负荷(TMB-H)、高微卫星不稳定(MSI-H)及错配修复缺陷(dMMR)的种族/民族分布及临床特征。结果显示22%患者生物标志物阳性,非西班牙裔黑人患者阳性率仅9%,显著低于其他种族/民族的26%。生物标志物阳性与较低死亡风险相关(aHR 0.63,95%CI 0.46-0.88),作者认为需前瞻性研究阐明这些分子差异对治疗和结局的影响。

要点

  • 742例子宫内膜癌患者中22%为生物标志物阳性,其中12%同时TMB-H和MSI-H/dMMR。
  • 非西班牙裔黑人患者生物标志物阳性率仅9%,其他种族/民族患者为26%。
  • 生物标志物阳性与较低死亡风险相关(aHR 0.63,95%CI 0.46-0.88)。

核心结论

  • 不到10%的非西班牙裔黑人子宫内膜癌患者具有TMB-H和/或MSI-H/dMMR,生物标志物阳性与生存改善相关。
  • 作者认为需要前瞻性研究阐明这些分子差异如何影响治疗和结局。

研究设计与样本

  • 子宫内膜癌分子靶向治疗联盟为经中心核实的临床和分子数据库。
  • 纳入接受肿瘤分子谱分析的子宫内膜癌患者,共742例。
  • TMB-H定义为每兆碱基≥10-12个突变。
  • MSI-H通过下一代测序或聚合酶链反应确定,dMMR通过免疫组化检测MLH1、MSH2、MSH6或PMS2缺失确定。
  • 肿瘤生物标志物阳性定义为TMB-H和/或MSI-H/dMMR。

主要发现

  • 742例患者中22%(n=164)为生物标志物阳性。
  • 12%(n=87)同时具有TMB-H和MSI-H/dMMR,8%(n=63)仅MSI-H/dMMR,2%(n=14)仅TMB-H。
  • 非西班牙裔黑人患者中仅9%为生物标志物阳性,其他种族/民族患者为26%。
  • 致病性POLE突变罕见(<1%,n=5)。
  • TMB-H患者中高风险组织学类型比例为43%,MSI-H/dMMR患者为24%。

局限性

  • 作者认为需要前瞻性研究阐明这些分子差异如何影响治疗和结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Mismatch repair deficiency (dMMR), high microsatellite instability (MSI-H), and high tumor mutation burden (TMB-H) are predictive and prognostic biomarkers in endometrial cancer. We aimed to characterize the racial/ethnic distribution of molecular markers and the clinical characteristics among endometrial cancer patients with TMB-H and MSI-H/dMMR. METHODS: The Endometrial Cancer Molecularly Targeted Therapy Consortium is a centrally verified clinical and molecular repository. Patients with endometrial cancer who underwent tumor profiling were included. TMB-H was defined as ≥10-12 mutations per megabase. MSI-H was determined by next-generation sequencing or polymerase chain reaction, and dMMR by loss of MLH1, MSH2, MSH6, or PMS2 on immunohistochemistry. Tumor biomarker positivity was defined as TMB-H and/or MSI-H/dMMR. Overall survival was assessed using Kaplan-Meier and Cox proportional hazard models. RESULTS: Among 742 patients, 22 % (n = 164) were biomarker positive: 12 % (n = 87) had both TMB-H and MSI-H/dMMR, 8 % (n = 63) had MSI-H/dMMR alone, and 2 % (n = 14) had 14 TMB-H alone. Only 9 % of non-Hispanic Black patients had biomarker positive tumors compared to 26 % of patients from other racial/ethnic groups. Pathogenic POLE mutations were rare (<1 %, n = 5). Patients with TMB-H had a higher proportion of high-risk histologies (43 %) than those with MSI-H/dMMR (24 %). Biomarker positive tumors were associated with a lower risk of death compared to biomarker negative tumors (aHR 0.63, 95 % CI: 0.46, 0.88). CONCLUSION: Less than 10 % of non-Hispanic Black patients with endometrial cancer had TMB-H and/or MSI-H/dMMR, and biomarker positivity was associated with improved survival. Prospective studies are necessary to elucidate how these molecular differences impact treatment and outcomes.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Lee SS, Secord AA, Friedman S, et al. Molecular characteristics by race and ethnicity of patients with high tumor mutational burden, high microsatellite instability, and mismatch repair deficiency: Real-world data from the multi-institutional Endometrial cancer Molecularly Targeted Therapy Consortium (ECMT2). Gynecol Oncol. 2025. PMID: 40651147. doi:10.1016/j.ygyno.2025.07.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。